Corpus Intelligence IC Memo — HOLLAND HOSPITAL 2026-04-26 11:18 UTC
IC Memo — HOLLAND HOSPITAL
Investment Committee Memorandum | MI | 189 beds | Grade C | EBITDA uplift $19.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOLLAND HOSPITAL

CCN 230072 | OTTAWA, MI | 189 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOLLAND HOSPITAL is a 189-bed under-performing / distressed in OTTAWA, MI with $262.3M in net patient revenue and a -7.2% operating margin. The hospital serves a payer mix of 16.3% Medicare, 16.5% Medicaid, and 67.3% commercial.

Thesis: Undervalued. Our ML models identify $19.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -7.2% to 0.1% (+736bps).

Net Revenue HCRIS$262.3M
Current EBITDA COMPUTED$-18.9M
Operating Margin COMPUTED-7.2%
Occupancy HCRIS40.0%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS34.0%
Distress Probability ML53.5%

2. Market Context & Competitive Position

163
MI Hospitals
-5.2%
State Median Margin
54
Comparable Hospitals

MI has 163 Medicare-certified hospitals with a median operating margin of -5.2%. The target's margin of -7.2% places it below the state median. Among 54 size-comparable peers (94-378 beds), the median margin is -6.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (94-378), prioritizing same-state peers. 54 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOLLAND HOSPITAL (Target)MI189$262.3M-7.2%
W.A. FOOTE MEMORIAL HOSPITALMI331$681.8M-9.0%
TRINITY HEALTH MUSKEGONMI262$621.2M-15.5%
TRINITY HEALTH GRAND RAPIDSMI271$601.8M-27.3%
HENRY FORD HEALTH MACOMB HOSPIMI303$584.5M-6.9%
MYMICHIGAN MEDICAL CENTER MIDLMI195$537.8M-9.6%
METROPOLITAN HOSPITALMI201$512.0M-11.3%
LAKELAND MEDICAL CENTER ST. JMI235$488.2M-3.6%
TRINITY HEALTH OAKLANDMI333$480.5M-7.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $19.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.5M+210bp18mo
Cost to Collect4.5%2.5%$5.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.2M+122bp9mo
Clean Claim Rate88.0%96.0%$168K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.5M
Cost to Collect
$5.2M
Denial Rate Reduction
$5.2M
A/R Days Reduction
$3.2M
Clean Claim Rate
$168K
Total EBITDA Uplift$19.3M
Current EBITDA$-18.9M
+ RCM Uplift+$19.3M
Pro Forma EBITDA$382K
Current Margin-7.2%
Pro Forma Margin0.1%
WC Released (1x)$10.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-29.1M$68.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-29.1M$65.6M0.00x-100.0%
Bull Case9.0x11.0x$-26.2M$119.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-26.2M$123.0M0.00x-100.0%
Bear Case11.0x10.0x$-32.0M$-18.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-32.0M$-31.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 53.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 54 hospitals with 94-378 beds
  • Same-state prioritization (n=55)
  • Comp margins: P25=-13.6% / P50=-6.9% / P75=-0.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.